| Literature DB >> 32735352 |
Jia Shen1,2,3,4, Luying Guo1,2,3,4, Pengpeng Yan1,2,3,4, Jingyi Zhou1,2,3,4, Qin Zhou1,2,3,4, Wenhua Lei1,2,3,4, Haitao Liu5, Guangjun Liu1,2,3,4, Junhao Lv1,2,3,4, Feng Liu5, Hongfeng Huang1,2,3,4, Wenzhao Dong5, Liping Shu5, Huiping Wang1,2,3,4, Jianyong Wu1,2,3,4, Jianghua Chen1,2,3,4, Rending Wang1,2,3,4,6.
Abstract
Donor-derived cell-free DNA (dd-cfDNA) is a promising biomarker for monitoring allograft status. However, whether dd-cfDNA can reflect real-time anti-rejection treatment effects remains unclear. We prospectively recruited 28 patients with acute renal rejection, including 5 with ABMR, 12 with type IA or type IB rejection, and 11 with type IIA or IIB rejection. dd-cfDNA levels in peripheral blood were measured using human single nucleotide polymorphism (SNP) locus capture hybridization. The percentage of dd-cfDNA (dd-cfDNA%) declined significantly from 2.566 ± 0.549% to 0.773 ± 0.116% (P < .001) after anti-rejection therapy. The dd-cfDNA% decreased steadily over the course of 3 days with daily methylprednisolone injections, but no significant difference in the dd-cfDNA% was observed between the end of anti-rejection therapy and 2 weeks later. Changes in the dd-cfDNA% (∆dd-cfDNA%) demonstrated a positive correlation with estimated glomerular filtration rates at 1 month (ρ = 2.570, P = .022), 3 months (ρ = 3.210, P = .027), and 6 months (ρ = 2.860, P = .019) after therapy. Thus, the dd-cfDNA assay shows prognostic capabilities in therapy outcome and allograft recovery; however, its ability is inhibited by methylprednisolone regardless of the types of rejection. Additionally, a reassessment of frequency intervals for testing is required.Entities:
Keywords: acute rejection; donor-derived cell-free DNA; kidney transplantation; prognosis
Mesh：
Substances：
Year: 2020 PMID： 32735352 DOI： 10.1111/ctr.14053
Source DB: PubMed Journal: Clin Transplant ISSN： 0902-0063 Impact factor: 2.863